Danaher Corporation in the news

Danaher's stock is potentially 4% undervalued, as its recent AI lab launch and portfolio reshaping align its current share price with future cash flow projections.

Murali Venkatesan, the global head of Danaher Ventures, has departed from the company, with Julie Sawyer Montgomery taking over his role.

Baird raised its price target for Danaher to $246 from $238, based on various weighted rating composites.

Danaher is launching an AI-powered autonomous lab in early 2027 to accelerate the development of custom antibodies and molecular tools using AI, robotics, and integrated Danaher technologies.

Danaher is launching an AI-powered autonomous lab to accelerate the discovery and development of custom antibodies and molecular tools in life sciences research.

Danaher Corporation is launching an AI-powered autonomous lab to accelerate custom antibody and molecular tool development by combining AI, robotics, and technologies from its operating companies.

Danaher Corporation is launching an AI-powered autonomous lab to develop custom antibodies and molecular tools faster and more efficiently.

Danaher Corporation is launching an AI-powered autonomous lab for antibody research, expected to operate at scale by early 2027, aiming to significantly speed up reagent discovery and generation.

Danaher is launching an AI-powered autonomous lab to accelerate drug discovery by developing custom antibodies and molecular tools more efficiently.

Danaher Corporation is launching an AI-backed autonomous lab and has various strong financial and ESG ratings.

Danaher Corporation is launching an AI-powered autonomous lab to accelerate the development of custom antibodies and molecular tools, combining artificial intelligence, robotics, and its technologies.

Danaher Corporation launched an AI-powered autonomous lab, set to operate at scale by early 2027, to accelerate scientific discovery and reagent production.

Danaher is launching an AI-powered autonomous lab to develop custom antibodies and molecular tools faster and more efficiently.

Barclays adjusted its price target for Danaher from $230 to $255 and maintained an "Overweight" rating.

Danaher Corp.'s stock decreased by 2.53% on Tuesday to $215.61, ending a two-day winning streak, but still outperformed competitors.

Danaher's future performance hinges on bioprocessing recovery and diagnostics growth amidst a shifting life science tools and diagnostics landscape.

Danaher Corporation's stock has underperformed the market in the past year, trading at a premium 25x 2026 earnings despite only 3-4% projected core revenue growth, while recent Q2 results show a recovery with a 5.5% revenue increase and strategic acquisition of Masimo.

Danaher Corp shares rose 3.3% to $221.21, and the stock is considered 5.9% undervalued according to GF Value™, despite significant insider selling over the past year.

Danaher Corporation, Illumina, and Reliance are listed in relation to the FactSet Research Systems Inc. provided CUSIP Database.

Danaher Corporation reported stronger-than-expected Q2 2026 revenue and EPS, with revenue growing 5.5% and analysts raising price targets.